March 2020

Supply Centered Synthesis to Current Late-State Intermediate: (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 5-hydroxy-1,3-oxathiolane-2-carboxylate

Medicines for All


June 2019

Continuous synthesis of the pyridone in route to dolutegravir

Medicines for All


April 2019

Synthesis of 5-Fluorocytosine Using 2-Cyano-2-fluoroethenolate as a Key Intermediate

Jule-Philipp Dietz, Brenden P. Derstine, Dorota Ferenc, Evan T. Crawford, Anthony J. Arduengo III, B. Frank Gupton, D. Tyler McQuade, and Till Opatz


March 2019

A Holistic Approach to Streamlining Pharmaceutical Processes: A Conversation

B. Frank Gupton and D. Tyler McQuade


January 2019

5-fluorocytosine

Medicines for All


January 2019

Process Design and Optimization for the Continuous Manufacturing of Nevirapine, an Active Pharmaceutical Ingredient for HIV Treatment

Samir Diab, D. Tyler McQuade, B. Frank Gupton, and Dimitrios I. Gerogiorgis


May 2018

7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir

Robert E. Ziegler, Bimbisar K. Desai, Jo-Ann Jee, B. Frank Gupton, Thomas D. Roper, and Timothy F. Jamison


May 2017

Increasing global access to the high-volume HIV drug nevirapine through process intensification

Jenson Verghese, Caleb J. Kong, Daniel Rivalti, Eric C. Yu, Rudy Krack, Jesus Alcázar, Julie B. Manley, D. Tyler McQuade, Saeed Ahmad, Katherine Belecki and B. Frank Gupton


May 2015

The Medicines for All Initiative: the nevirapine process optimization

Medicines for All


November 2015

The Medicines for All Initiative: continuous synthesis of nevirapine and reaction monitoring with online PAT

Medicines for All